Contact us

Support


Home > Investment tools > They choose Russia > Gilead Sciences, Inc.

Gilead Sciences, Inc.

Gilead Sciences and Pharmstandard announced conclusion of the agreement under which Sovaldi® (sofosbuvir) drugs for the treatment of chronic hepatitis C and Truvada® (emtricitabine/tenofovir disoproxil fumarate) for HIV treatment will be produced at the Pharmstandard facilities.

31 August 2018
https://pharmstd.ru/
Investor

Investor profile

Gilead Sciences, Inc.

USA

Company's website: http://www.gilead.com

T: (650) 574-3000

Public Company

E-mail: public_affairs@gilead.com

Contact: John F. Milligan, PhD, President and CEO

Gilead Sciences, Inc. is a research biopharmaceutical company developing and introducing innovative medicines into clinical practice for the use in fields where there are unmet medical needs. The company aims to transform and simplify the treatment of people with life-threatening diseases at the global scale. Gilead operates in more than 35 countries. The company is headquartered in Foster City, California.

Subscribe to Newsletters

Email: